Holen Sie sich die Stockscreener-App
98.86
8.37%
-9.03
Handel nachbörslich:
99.99
1.13
+1.14%
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: - GlobeNewswire
Axsome reports positive results for Alzheimer’s and migraine treatments - Investing.com India
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Sees Large Decline in Short Interest - MarketBeat
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - The Manila Times
Axsome reports positive results for Alzheimer’s and migraine treatments By Investing.com - Investing.com UK
Axsome Phase 3 Results: Breakthrough Data for Alzheimer's and Narcolepsy | AXSM Stock News - Stock Titan
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by DnB Asset Management AS - MarketBeat
Axsome to battle on with solriamfetol despite mixed data - The Pharma Letter
KLP Kapitalforvaltning AS Makes New $745,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More - Yahoo Finance
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol - MSN
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap DownTime to Sell? - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from Needham & Company LLC - MarketBeat
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $187 From $200, Maintains Buy Rating - MarketScreener
Corient Private Wealth LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure - insights.citeline.com
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week - MSN
Why Shares of Axsome Therapeutics Slumped Today - Yahoo
Axsome shares fall after trial results disappoint By Investing.com - Investing.com Canada
Axsome Must Face Securities Fraud Suit Over Migraine Drug Delays - Bloomberg Law News
Axsome falls on depression drug's trial setback - TradingView
Mizuho maintains Axsome stock Outperform amid trial setback - Investing.com
BofA maintains Buy rating on Axsome shares with $174 target - Investing.com
Guggenheim maintains Buy on Axsome stock, price target at $195 - Investing.com
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder - Benzinga
Axsome Therapeutics: Promising Market Opportunity for Solriamfetol in Severe EDS Subgroup Boosts Buy Rating - TipRanks
Positive Outlook for Axsome Therapeutics Amid Mixed Trial Results and Upcoming FDA Application - TipRanks
P2P Group Ltd. Investor Presentation - The Globe and Mail
Axsome to narrow focus of depression drug trial after limited success in initial run - MarketScreener
Axsome stock slips as depression trial fails (AXSM:NASDAQ) - Seeking Alpha
S&P 500 Futures Fall in Premarket Trading; Axsome Therapeutics, First Horizon Lag - MarketWatch
Why Is Axsome Therapeutics Stock Falling In Pre-market? - Nasdaq
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) - The Manila Times
Axsome’s solriamfetol shows promise in MDD with EDS subgrou - Investing.com
Axsome's depression treatment fails to meet main goal of late-stage study - TradingView
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of - Bluefield Daily Telegraph
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup - Stock Titan
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $216.00 - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat
Loomis Sayles & Co. L P Sells 8,475 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4.9%Here's Why - MarketBeat
Fox Run Management L.L.C. Makes New $518,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Proactive Strategies - Stock Traders Daily
Cibc World Markets Corp Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome succeeds in late-stage trial for ADHD therapy - MSN
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views - Benzinga
Medical Properties Trust : Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - MarketScreener
Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data - BioPharma Dive
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating - Marketscreener.com
Axsome’s Sunosi succeeds in Phase III ADHD trial - Yahoo Finance
13,460 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by HighTower Advisors LLC - MarketBeat
Intech Investment Management LLC Acquires 5,087 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):